November 13, 2025
1 min watch
PHOENIX — In this video, Paul Kwo, MD, discusses preliminary results from the phase 3 MAESTRO-NAFLD-1 trial assessing resmetirom in patients with compensated metabolic dysfunction-associated steatohepatitis cirrhosis.
“There’s a larger effort ongoing, but this initial glimpse suggests that there may be benefit to resmetirom in patients with cirrhosis, in addition to its known benefit in those who have stage 2 to 3 fibrosis,” Kwo, professor of medicine and director of hepatology at Stanford University, told Healio.
Results presented at ACG Annual Scientific Meeting showed that among 122 patients with MASH and well-compensated cirrhosis who received 80 mg resmetirom (Madrigal Pharmaceuticals) for up to 2 years, more than 50% had a sustained reduction in liver stiffness of at least 25%.
Improvements were also reported in several biomarkers and imaging assessments, and treatment with resmetirom was well tolerated.
For more information:
Paul Kwo, MD, can be reached at pkwo@stanford.edu.
Sources/Disclosures
Source:
Healio Interviews
Reference:
- Alkhouri N, et al. Treatment with resmetirom for up to two years led to improvement in liver stiffness, fibrosis biomarkers, fibrosis scores and portal hypertension in 122 patients with compensated MASH cirrhosis. Presented at: ACG Annual Scientific Meeting; Oct. 24-29, 2025; Phoenix (hybrid meeting).
Disclosures:
Kwo reports consulting, advising or review panel roles with AbbVie, Aligos Therapeutics, Drug Farm, Durect, Gilead Sciences, HepQuant, Inventiva Pharma and Surrozen; grant or research support from Altimmune, Fractyl Health, Gilead, Inventiva, Madrigal Pharmaceuticals, Novo Nordisk, Target Registries and Ultragenyx; and stock options in Durect.
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
